Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000665139 | SCV000789207 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2017-01-24 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000694014 | SCV000822439 | pathogenic | Qualitative or quantitative defects of dysferlin | 2023-11-27 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 5 of the DYSF gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in DYSF are known to be pathogenic (PMID: 17698709, 20301480). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. Disruption of this splice site has been observed in individuals with DYSF-related conditions (PMID: 36580222). This variant is also known as c.460+1G>A. ClinVar contains an entry for this variant (Variation ID: 550404). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Neuberg Centre For Genomic Medicine, |
RCV000665139 | SCV004171311 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2B | criteria provided, single submitter | clinical testing | ||
Natera, |
RCV000665139 | SCV002079752 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2021-03-31 | no assertion criteria provided | clinical testing |